$MIRA News

MIRA Pharma Executes Amended And Restated Exclusive License Agreement With MIRALOGX, Securing Worldwide Exclusive Rights To MIRA-55 And SKNY-1

MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN

MIRA Pharmaceuticals Executes Amendment To Its Exclusive Ketamir-2 License Agreement With MIRALOGX To Expand Licensed Territory

MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2

MIRA Pharma Announces Unblinded Results From Completed Phase 1 Clinical Trial Evaluating Ketamir-2, Proprietary Selective Oral NMDA Receptor Modulator

MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate

MIRA Pharmaceuticals Announces Acceptance And Publication Of A Peer-Reviewed Manuscript On SKNY-1 In The International Journal Of Molecular Sciences

What's Going On With MIRA Pharma Stock Tuesday?

MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies

MIRA Pharmaceuticals shares are trading higher after the company announced new preclinical data demonstrating that Mira-55 did not produce cannabinoid-like central nervous system side effects across a comprehensive battery of validated behavioral assays.

MIRA Pharmaceuticals shares are trading higher after the company announced new preclinical data demonstrating that Mira-55 did not produce cannabinoid-like central nervous system side effects across a comprehensive battery of validated behavioral assays.

MIRA Pharma Announces New Preclinical Data Demonstrating Mira-55 Did Not Produce Cannabinoid-Like CNS Side Effects Across Comprehensive Battery Of Validated Behavioral Assays

MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2

Mira Pharmaceuticals Completes Patient Dosing In Phase 1 Clinical Study Of Ketamir-2; No Serious Adverse Events, Dose-Limiting Toxicities Seen; Plans To File Phase 2a Clinical Trial, Supporting Documents To FDA In H1

MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study

MIRA Pharmaceuticals Initiated Dosing In Final Cohort of Its Phase 1 Multiple Ascending Dose Trial Of Ketamir-2; The Company Expects to Complete the Phase 1 Clinical Program by the End of Q1 of 2026

Mira Pharmaceuticals Initiates Dosing Final Group Of Its Phase 1 Multiple Ascending Dose Clinical Study Of Ketamir-2

Starfish Space Completes Autonomous Rendezvous and Proximity Mission in LEO with Impulse Space

Mira Pharmaceuticals Q3 EPS $(1.18) Misses $(0.08) Estimate

Specialist Direct's ‘Mira’ Partners with dacadoo to Transform Recovery Management and Wellness Outcomes